Kratom shares some pharmacological overlap with opioids but differs in important ways that affect its safety profile, addictive potential, and the experience of using it. The plant’s main active compound, mitragynine, is a partial agonist at the mu-opioid receptor, the same receptor targeted by drugs like morphine, oxycodone, and fentanyl. But “partial” is the operative word: mitragynine activates that receptor only about a third as strongly as a full opioid agonist, and it triggers a different set of downstream signals inside cells. That distinction ripples outward into nearly every comparison you might want to make between kratom and conventional opioids, from overdose risk to withdrawal severity to the complicated question of whether kratom helps or hurts people trying to quit stronger drugs.
How Kratom Interacts with Opioid Receptors
The comparison to opioids starts at the molecular level. Mitragynine, the most abundant alkaloid in kratom leaves, binds to the mu-opioid receptor but only partly activates it. In lab assays measuring receptor signaling, mitragynine reached roughly 34% of the maximum effect produced by a full agonist, while its more potent oxidized cousin, 7-hydroxymitragynine, reached about 47%.1PubMed Central. Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators Full opioid agonists like morphine or fentanyl push that activation to 100%. This is why kratom produces opioid-like effects, pain relief and mild euphoria, but generally not to the same intensity as prescription painkillers or heroin.
Beyond its partial agonism at the mu receptor, mitragynine acts as an antagonist at the kappa and delta opioid receptors, meaning it blocks rather than activates them.1PubMed Central. Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators This is unusual. Classical opioids tend to activate multiple opioid receptor subtypes at once. Kappa-receptor activation, for instance, is associated with the unpleasant dysphoria that some strong opioids cause. The fact that mitragynine blocks that receptor may partly explain why kratom’s subjective effects feel qualitatively different from heavier opioids.
The G-Protein Bias That Changes the Safety Equation
When an opioid activates the mu receptor, the cell can respond through two main signaling pathways. One involves G proteins, which mediate pain relief. The other involves a molecule called beta-arrestin, which is linked to respiratory depression, constipation, and tolerance. Classical opioids activate both pathways robustly. Kratom alkaloids almost exclusively favor the G-protein pathway. In cell-based assays, both mitragynine and 7-hydroxymitragynine produced no measurable beta-arrestin recruitment, even under conditions designed to amplify that signal.1PubMed Central. Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators This strong bias was confirmed across all three opioid receptor subtypes in a separate study that also tested four kratom alkaloids side by side.2PubMed Central. G protein-biased kratom-alkaloids and synthetic carfentanil-amide opioids as potential treatments for alcohol use disorder
This matters for a practical reason: the beta-arrestin pathway is a major contributor to the respiratory depression that kills people in opioid overdoses. A drug that delivers pain relief through G proteins while largely skipping the beta-arrestin side could, in theory, be analgesic without being as lethal in overdose. That theory plays out in animal data. In a head-to-head rodent study, oxycodone caused dose-dependent respiratory depression and sedation, with deaths at higher doses. Mitragynine, even at doses many times higher than what humans typically consume, produced no significant respiratory depression and no deaths.3PubMed Central. Respiratory effects of oral mitragynine and oxycodone in a rodent model A separate study found that mitragynine’s respiratory-depressant effects hit a ceiling: doses above a certain threshold didn’t suppress breathing any further, likely because the liver enzyme that converts mitragynine into its more potent metabolite, 7-hydroxymitragynine, gets saturated.4PubMed Central. The respiratory depressant effects of mitragynine are limited by its conversion to 7-OH mitragynine
Kratom Is Not Just an Opioid Mimic
Framing kratom as simply a “natural opioid” misses a significant part of the picture. The plant contains dozens of alkaloids, several of which act on non-opioid systems in the brain. Mitragynine itself interacts with adrenergic and serotonergic receptors, as well as neuronal calcium channels.5PubMed. An insight review on the neuropharmacological effects, mechanisms of action, pharmacokinetics and toxicity of mitragynine Two other kratom alkaloids, paynantheine and speciogynine, have high affinity for serotonin 5-HT1A receptors. In rat studies, both produced pain relief through a mechanism that was blocked by a serotonin-receptor antagonist, not an opioid-receptor antagonist, meaning the analgesic effect was independent of the opioid system entirely.6PubMed Central. Activity of Mitragyna speciosa (“Kratom”) Alkaloids at Serotonin Receptors
This multi-receptor activity helps explain something users have long reported: kratom feels different depending on how much you take. At low doses, it acts more like a stimulant, producing increased energy, sociability, and alertness. At high doses, the opioid-like sedation and pain relief become dominant.7PubMed Central. Kratom No classical opioid behaves this way. The stimulant-at-low-doses effect likely reflects the adrenergic and serotonergic activity that mitragynine and the other alkaloids bring to the table, activity that gets overshadowed by the opioid effects at higher doses. This dual profile is part of what makes kratom hard to classify neatly: it is not an opioid, not a stimulant, not a serotonergic drug, but something of all three depending on the dose and the particular blend of alkaloids in the product.
Dependence, Withdrawal, and Abuse Potential
Kratom can produce dependence with regular use, but the character and severity of that dependence differ from what you see with full opioid agonists. A scientific expert forum that reviewed the available evidence on kratom withdrawal concluded that while some symptoms overlap with opioid withdrawal (runny nose, muscle aches, diarrhea), others resemble sedative or stimulant withdrawal (lethargy, depressed mood, anxiety). The panel’s overall assessment was that kratom withdrawal is generally milder and more self-manageable than withdrawal from opioids, sedatives, or stimulants.8Drug and Alcohol Dependence Reports. Kratom withdrawal: Discussions and conclusions of a scientific expert forum
When researchers tested mitragynine for abuse potential using the standard battery of animal models, the results were notably weak compared to morphine-like opioids and stimulants. Mitragynine showed no rewarding effects in two widely used models of abuse liability, with only weak evidence in a third. The overall conclusion was that mitragynine has relatively low abuse potential compared to classical opioids and stimulants.9PubMed Central. Kratom Abuse Potential 2021: An Updated Eight Factor Analysis That said, kratom extracts and 7-hydroxymitragynine specifically did show rewarding effects in a study examining alcohol-reducing potential, a finding that distinguishes the crude plant from purified mitragynine.2PubMed Central. G protein-biased kratom-alkaloids and synthetic carfentanil-amide opioids as potential treatments for alcohol use disorder The practical implication: whole-plant kratom and concentrated extracts may not carry identical risk profiles, and 7-hydroxymitragynine-enriched products deserve more caution.
One review that attempted to weigh kratom’s overall risk-benefit balance as both a euphoriant and a potential pain medication concluded that while kratom has potential for abuse and addiction, it “appears to be less addictive and to have milder withdrawal symptoms than opioid drugs.”10PubMed Central. Mitragyna speciosa: Balancing Potential Medical Benefits and Abuse That characterization tracks with what users report but should be held loosely: the clinical evidence here is thin. A systematic review of the literature found no controlled human clinical trials on kratom for opioid use disorder and concluded that there is “insufficient evidence to allow any conclusions to be drawn” about efficacy or safety for that purpose.11PubMed. Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature
Where the Deaths Happen
The question of whether kratom kills people is more nuanced than headlines suggest. When researchers examined coroner toxicology reports for deaths involving kratom, a pattern emerged repeatedly: almost no one who died had used kratom alone. In one analysis of drug-intoxication-related deaths involving mitragynine, over 93% of the deceased had used multiple substances, and nearly 80% had also taken at least one opioid.12PubMed. The Associations of Kratom (Mitragynine), Opioids, Other Substances, and Sociodemographic Variables to Drug Intoxication-related Mortality Only about 6.5% of the mitragynine-positive deaths involved kratom as the sole substance. A smaller postmortem study told a similar story: all four deaths with kratom in the toxicology had accidental opioid overdose noted, and fentanyl was found in three of the four cases.13PubMed Central. Presence of kratom in opioid overdose deaths: findings from coroner postmortem toxicological report
This aligns with a broader observation from the literature: case reports of severe harm or death emerging from Western countries “frequently pertained to kratom used together with other substances,” a pattern largely absent in Southeast Asia, where the plant has a long history of use in traditional preparations. The combination of kratom with fentanyl, benzodiazepines, or other central-nervous-system depressants is far more dangerous than kratom alone, and much of the mortality attributed to kratom in public discourse actually reflects poly-drug toxicity. That does not mean kratom is risk-free in isolation, but it does mean the risk profile is dramatically different from the numbers that lump all kratom-positive deaths together.
Drug Interactions Worth Knowing About
Part of the danger in combining kratom with other substances is pharmacokinetic, not just pharmacodynamic. Mitragynine powerfully inhibits CYP2D6, a liver enzyme that metabolizes a wide range of drugs including certain antidepressants, antipsychotics, and some opioids like codeine and tramadol. It also acts as a time-dependent inhibitor of CYP3A4, which processes an even larger share of common medications.14PubMed Central. Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations When kratom inhibits these enzymes, other drugs that depend on them for clearance can build up to dangerously high levels in the blood. Modeling predicted that a typical kratom dose could increase the blood levels of midazolam, a benzodiazepine, by nearly six-fold.14PubMed Central. Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations CYP3A4 is also the enzyme responsible for converting mitragynine itself into 7-hydroxymitragynine, the more potent metabolite, which creates a complicated feedback loop where the drug essentially slows its own activation at higher doses.15Drug Metabolism and Disposition. Translating Kratom-Drug Interactions: From Bedside to Bench and Back
For people taking prescription medications, these interactions are the most immediate real-world hazard from kratom. You can respect kratom’s relatively milder opioid effects and still get into serious trouble if it causes your other medications to accumulate beyond safe levels. The risk is particularly high with benzodiazepines, certain pain medications, and some psychiatric drugs.
Liver Injury
Kratom has been linked to liver damage in a small number of cases. The U.S. Drug Induced Liver Injury Network identified eleven cases attributed to kratom, with all patients developing jaundice at a median of about two weeks after starting use. The majority required hospitalization, though all eventually recovered.16PubMed Central. Liver Injury Associated with Kratom, A Popular Opioid-Like Product: Experience from the U.S. Drug Induced liver Injury Network Individual case reports of cholestatic hepatitis from kratom have also been documented.17PubMed Central. Kratom-Induced Cholestatic Liver Injury and Its Conservative Management This appears to be a rare idiosyncratic reaction rather than a predictable dose-dependent toxicity, but it’s worth knowing about, particularly for people who use kratom daily or who have pre-existing liver conditions. Classical opioids carry their own liver risks, most commonly through the acetaminophen co-formulated in combination products like Vicodin, but the mechanism is different.
Contamination in an Unregulated Market
Unlike prescription opioids, which arrive in standardized doses from regulated manufacturers, most kratom sold in the United States is an unregulated botanical product. This creates two problems. First, the alkaloid content varies substantially based on the plant’s genetics, the season of harvest, and how the leaves are handled after picking.18PubMed Central. Alkaloid biosynthesis in medicinal crop kratom (Mitragyna speciosa) varies with postharvest, genetic, and seasonal factors Two bags of kratom powder from different sources can contain very different concentrations of mitragynine and 7-hydroxymitragynine, making consistent dosing difficult.
Second, contamination is a real issue. Testing of kratom products sold in the U.S. has found that many contain potentially hazardous levels of lead.19PubMed Central. Public Health Implications and Possible Sources of Lead (Pb) as a Contaminant of Poorly Regulated Kratom Products in the United States A broader analysis of heavy metals in kratom products found that non-extract forms like powders and capsules tend to have higher concentrations of lead and arsenic than extract products, and that daily use of these products can result in exposures exceeding regulatory safety thresholds.20PubMed. Elemental impurities (heavy metals) in kratom products: an assessment of published individual product analyses When people experience adverse effects from kratom, it can be difficult to know whether the harm came from the alkaloids themselves or from contaminants in the product, a confounding factor that muddies the safety data.
Who Uses Kratom and Why
Kratom use in the U.S. is concentrated among a middle-aged, middle-income population. An early online survey found that users were predominantly 31 to 50 years old with household incomes above $35,000, and that pain management and treatment of emotional or mental conditions were the top reported reasons for use.21PubMed. Patterns of Kratom use and health impact in the US-Results from an online survey More recent research paints a consistent picture: about half of kratom consumers meet criteria for chronic pain, and a majority report difficulties obtaining adequate pain treatment through conventional channels, difficulties that influenced their decision to try kratom.22PubMed Central. Kratom (Mitragyna speciosa) use for self-management of pain: Insights from cross-sectional and ecological momentary assessment data In a daily tracking study, pain relief was the most frequently endorsed motivation for use, regardless of whether someone had a chronic pain diagnosis.
A latent-class analysis identified at least four distinct groups of U.S. kratom consumers. The largest group, about a third of users, used kratom primarily for chronic pain. Another fifth used it as a long-term replacement for other substances. The remaining two groups used it mainly for managing anxiety or depression and for recreation.23PubMed. At least four groups of kratom consumers in the United States: latent-class analysis of motivations for kratom use The recreational segment is smaller than you might expect given the public narrative. When the FDA solicited public comments on kratom scheduling, fewer than 2% of respondents reported recreational use, abuse potential, or adverse effects.24PubMed Central. Qualitative content analysis of public responses to an FDA inquiry on the impact of scheduling changes to kratom That figure obviously reflects selection bias, since people motivated to comment on scheduling tend to be those who view kratom favorably, but it reinforces the finding that most self-reported use is for pain, mood, or substance-replacement purposes rather than getting high.
How Traditional and Western Use Patterns Diverge
In Southeast Asia, where kratom grows natively, the traditional mode of use is chewing fresh leaves or brewing them into tea. Workers in Thailand and Malaysia have used kratom this way for generations, primarily as a mild stimulant to manage fatigue during manual labor. The alkaloid content in fresh leaves is lower and less concentrated than in the processed powders, capsules, and especially concentrated extracts sold in Western markets. A review of the literature found that while several cases of toxicity and death have been reported among Western users, such reports have been essentially absent in Southeast Asian populations with a much longer history of use. The authors attributed this to differences in preparation, the tendency toward poly-drug use in Western settings, and the higher potency of commercial products compared to fresh leaves.
This gap between traditional and commercial kratom is worth sitting with. A fresh leaf chewed in a field in Thailand delivers a relatively consistent, modest dose of mitragynine along with whatever moderating effects the other alkaloids provide. A concentrated extract capsule sold in an American gas station may contain many times more 7-hydroxymitragynine, may be contaminated with heavy metals, and is more likely to be combined with other drugs. The safety profile of kratom depends heavily on which version of kratom you’re talking about, and much of the public debate conflates them.
The Therapeutic Potential That Has Not Been Tested
Kratom’s pharmacological profile, partial mu-opioid agonism with G-protein bias and multi-receptor activity, is genuinely interesting from a drug-development standpoint. A systematic review cataloging its range of activity noted that mitragynine and related alkaloids show therapeutic potential for managing multiple pain types, including neuropathic and inflammatory pain.25PubMed Central. Exploring the Therapeutic Potential of Mitragynine and Corynoxeine: Kratom-Derived Indole and Oxindole Alkaloids for Pain Management The G-protein-biased signaling that separates it from classical opioids is precisely the kind of pharmacology that pharmaceutical researchers have been trying to engineer from scratch for years, hoping to create painkillers that relieve pain without the respiratory depression and high addiction potential of existing opioids.
Yet the irony is that despite millions of Americans already using it, kratom has never been tested in a controlled human clinical trial for any indication.11PubMed. Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature Everything known about its efficacy comes from animal studies, cell-based assays, and self-reported surveys of users. Those surveys consistently report high satisfaction and perceived effectiveness, but surveys of unblinded self-selected users are among the weakest forms of evidence in medicine. The pharmacology is promising; the clinical proof is simply missing. Whether kratom is a safer alternative to opioids, a stepping stone between them and sobriety, or a risk that outweighs its benefits remains a question that can only be answered by the kind of rigorous human research that has not yet been done.